Contrasting of Brainstorm Cell Therapeutics Inc. (BCLI) and HOOKIPA Pharma Inc. (NASDAQ:HOOK) – MS Wkly

This is therefore a contrasting of the institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and HOOKIPA Pharma Inc. (NASDAQ:HOOK). The two are both Biotechnology companies that compete with one another.

Earnings and Valuation

Demonstrates Brainstorm Cell Therapeutics Inc. and HOOKIPA Pharma Inc. earnings per share (EPS), gross revenue and valuation.

Profitability

Table 2 represents Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) and HOOKIPA Pharma Inc. (NASDAQ:HOOK)s return on assets, return on equity and net margins.

Liquidity

1 and 1 are the respective Current Ratio and a Quick Ratio of Brainstorm Cell Therapeutics Inc. Its rival HOOKIPA Pharma Inc.s Current and Quick Ratios are 5.6 and 5.6 respectively. HOOKIPA Pharma Inc. has a better chance of clearing its pay short and long-term debts than Brainstorm Cell Therapeutics Inc.

Analyst Recommendations

Ratings and Recommendations for Brainstorm Cell Therapeutics Inc. and HOOKIPA Pharma Inc. can be find in next table.

Brainstorm Cell Therapeutics Inc. has a consensus price target of $9, and a 140.00% upside potential. On the other hand, HOOKIPA Pharma Inc.s potential upside is 124.82% and its consensus price target is $18.75. The information presented earlier suggests that Brainstorm Cell Therapeutics Inc. looks more robust than HOOKIPA Pharma Inc. as far as analyst belief.

Institutional & Insider Ownership

The shares of both Brainstorm Cell Therapeutics Inc. and HOOKIPA Pharma Inc. are owned by institutional investors at 11.4% and 35.9% respectively. Insiders owned roughly 0.6% of Brainstorm Cell Therapeutics Inc.s shares. Comparatively, insiders own roughly 0.9% of HOOKIPA Pharma Inc.s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Brainstorm Cell Therapeutics Inc. had bullish trend while HOOKIPA Pharma Inc. had bearish trend.

Summary

On 6 of the 11 factors Brainstorm Cell Therapeutics Inc. beats HOOKIPA Pharma Inc.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinsons disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. Its NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in Hackensack, New Jersey.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

View original post here:
Contrasting of Brainstorm Cell Therapeutics Inc. (BCLI) and HOOKIPA Pharma Inc. (NASDAQ:HOOK) - MS Wkly